Literature DB >> 19004411

Imiquimod in vulvar Paget's disease: a case report.

John P Geisler1, Kelly J Manahan.   

Abstract

BACKGROUND: Vulvar Paget's disease is a relatively rare gynecologic neoplasm that is problematic because of its propensity to recur. CASE: An 80-year-old woman was found to have recurrent Paget's disease of the vulva. She was initially diagnosed 12 years previously and had had multiple resections for the disease. She was found to have histologically proven Paget's disease and underwent a course of topical immune modulator therapy with imiquimod. Biopsy proved histologic regression of the disease progress. The patient remained without recurrence 12 months after therapy.
CONCLUSION: In select patients imiquimod may be used to treat or facilitate treatment of vulvar Paget's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004411

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  4 in total

1.  Treatment of vulvar Paget disease with topical imiquimod: a case report and review of the literature.

Authors:  Laurence Feldmeyer; Katrin Kerl; Jivko Kamarashev; Pierre de Viragh; Lars E French
Journal:  J Dermatol Case Rep       Date:  2011-09-21

Review 2.  Effects of imiquimod on vulvar Paget's disease: a systematic review of literature.

Authors:  Hiroko Machida; Aida Moeini; Lynda D Roman; Koji Matsuo
Journal:  Gynecol Oncol       Date:  2015-07-17       Impact factor: 5.482

3.  Clinical treatment of vulvar Paget's disease: a case report.

Authors:  Cristina Anton; Arthur Vicentini da Costa Luiz; Filomena Marino Carvalho; Edmund Chada Baracat; Jesus Paula Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.